Physician profile
George A Smith
NPI 1861405862
$2,694.45
in general payments reported to CMS, 2019-2025
23 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $283 · 2021: $77.99 · 2022: $497 · 2023: $578 · 2024: $525 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.71 | 2020-2025 | Vraylar, Ubrelvy |
| Dexcom, INC. | $389.25 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $352.41 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $267.12 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $228.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $203.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Neurocrine Biosciences, INC. | $136.98 | 2022 | |
| Horizon Therapeutics Plc | $84.68 | 2019 | |
| Lilly USA, LLC | $79.98 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $75.80 | 2019-2023 | Fasenra |
| Amgen INC. | $71.77 | 2019-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $48.76 | 2022-2023 | |
| Astellas Pharma US INC | $43.89 | 2023-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $38.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.95 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.27 | 2024 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $23.58 | 2023 | |
| Sunovion Pharmaceuticals INC. | $20.23 | 2019 | |
| Abbott Laboratories | $16.16 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $15.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.81 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.42 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.